BR112022001330A2 - Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos - Google Patents

Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos

Info

Publication number
BR112022001330A2
BR112022001330A2 BR112022001330A BR112022001330A BR112022001330A2 BR 112022001330 A2 BR112022001330 A2 BR 112022001330A2 BR 112022001330 A BR112022001330 A BR 112022001330A BR 112022001330 A BR112022001330 A BR 112022001330A BR 112022001330 A2 BR112022001330 A2 BR 112022001330A2
Authority
BR
Brazil
Prior art keywords
pyridazin
diamino
pro
derivatives
pharmaceutical compositions
Prior art date
Application number
BR112022001330A
Other languages
English (en)
Inventor
Leticia Maragno Ana
András Herner
András Kotschy
Attila Paczal
Frédéric Colland
Brooke Murray James
Edward Paul Davidson James
Jérôme-Benoît Starck
Marianna Szigeti
Philip Dodsworth Mark
Maïa Chanrion
Miklós Nyerges
Monika Rudasová
Márk Molnár
Pál Timári Mátyás
Patrice Desos
Paul Webb
Petra Dunkel
Jane Parsons Rachel
Simon Bedford
Tibor Novák
Zoltán Madarász
Ágnes Strofek
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of BR112022001330A2 publication Critical patent/BR112022001330A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos. a presente invenção refere-se a compostos de fórmula (i), em que het1, het2, r1, r2 e r3 são como definidos na descrição. medicamentos.
BR112022001330A 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos BR112022001330A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
BR112022001330A2 true BR112022001330A2 (pt) 2022-05-17

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001330A BR112022001330A2 (pt) 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos

Country Status (19)

Country Link
US (1) US20220289734A1 (pt)
EP (1) EP4003988A1 (pt)
JP (1) JP2022542937A (pt)
KR (1) KR20220042182A (pt)
CN (1) CN114450283B (pt)
AR (1) AR119493A1 (pt)
AU (1) AU2020322072A1 (pt)
BR (1) BR112022001330A2 (pt)
CA (1) CA3148502A1 (pt)
CL (1) CL2021003594A1 (pt)
CO (1) CO2022000700A2 (pt)
CR (1) CR20220014A (pt)
IL (1) IL289932A (pt)
JO (1) JOP20220006A1 (pt)
MX (1) MX2022001161A (pt)
PE (1) PE20220704A1 (pt)
TW (1) TW202118761A (pt)
UY (1) UY38809A (pt)
WO (1) WO2021018857A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230143605A (ko) * 2020-11-24 2023-10-12 노파르티스 아게 Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
EP4288434A1 (en) * 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
AR129380A1 (es) 2022-05-20 2024-08-21 Novartis Ag Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EP2231656A1 (en) * 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR102601320B1 (ko) * 2015-05-29 2023-11-10 데이진 화-마 가부시키가이샤 피리도[3,4-d]피리미딘 유도체 및 그 약학적으로 허용되는 염

Also Published As

Publication number Publication date
MX2022001161A (es) 2022-02-22
CN114450283A (zh) 2022-05-06
US20220289734A1 (en) 2022-09-15
AR119493A1 (es) 2021-12-22
JOP20220006A1 (ar) 2023-01-30
UY38809A (es) 2021-02-26
IL289932A (en) 2022-03-01
EP4003988A1 (en) 2022-06-01
CL2021003594A1 (es) 2022-11-18
AU2020322072A1 (en) 2022-02-10
CR20220014A (es) 2022-03-02
KR20220042182A (ko) 2022-04-04
TW202118761A (zh) 2021-05-16
CO2022000700A2 (es) 2022-02-07
PE20220704A1 (es) 2022-05-04
JP2022542937A (ja) 2022-10-07
WO2021018857A1 (en) 2021-02-04
CA3148502A1 (en) 2021-02-04
CN114450283B (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
BR112022001330A2 (pt) Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
CL2022000102A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.
BR112018007155A2 (pt) novos compostos de espiro[3h-indol-3,2?-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112018014536A2 (pt) derivados de amônio, um processo para sua preparação e composições farmacêuticas contendo os mesmos
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112014030173A8 (pt) Composto derivado de benzimidazol-prolina, e, composição farmacêutica
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
GT200600518A (es) Derivados de pirimidina
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
CL2019003281A1 (es) Derivados de piperidina. (divisional solicitud 201900169)
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
BR112015013124A2 (pt) novos derivados de piridina
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112015020795A2 (pt) derivados de pirazol novos
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
BR112017018643A2 (pt) "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas"
BR112014018714A8 (pt) Compostos de 4-(benzoimidazol-2-il)-tiazol e derivados de aza relacionados